A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)

Sponsor
AbbVie
Study ID
NCT02986373
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • risankizumab — BIOLOGICAL
    Risankizumab administered by subcutaneous injection.

Study Details

This is an open-label extension (OLE) study to assess the efficacy, safety and tolerability of risankizumab in participants with psoriatic arthritis (PsA).

Key Dates

Start date
Dec 15, 2016
Status verified
May 2019
Primary completion
Jul 8, 2018
Completion
Jul 30, 2018

Study Design

Enrollment
145 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Risankizumab
    Participants received open-label risankizumab 150 mg by subcutaneous injection at Weeks 0, 12, 24, and 36.

Primary Outcome Measure

Number of Participants With Adverse Events [ Time Frame: From the first dose of study drug in this study until 20 weeks after the last dose of study drug (up to 56 weeks). ]

Related Studies